Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy

S. I. Helle; W. Mietlowski; J. P. Guastalla; I. Szakolczai; E. Bajetta; H. Sommer; E. Baltali; T. Pinter; M. Csepreghy; L. Ottestad; C. Boni; C. Bryce; J. G M Klijn; P. E. Lønning

doi:10.1016/j.ejca.2004.12.015

Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy

S. I. Helle, W. Mietlowski, J. P. Guastalla, I. Szakolczai, E. Bajetta, H. Sommer, E. Baltali, T. Pinter, M. Csepreghy, L. Ottestad, C. Boni, C. Bryce, J. G M Klijn, P. E. Lønning

Arcispedale Santa Maria Nuova

Research output: Contribution to journal › Article › peer-review

Abstract

The insulin-like growth factor (IGF)-system was evaluated in 150 breast cancer patients participating in a randomised phase III trial comparing octreotide pamoate and tamoxifen with tamoxifen + placebo. Alterations in the IGF-system in the two treatment arms and individual changes with respect to outcome were compared. Serum IGF-I and -II, free IGF-I, and insulin-like growth factor binding protein 1-3 (IGFBP1-3) were measured by radioimmmunoassay (RIA)/immunoradiometric assay (IRMA) and IGFBPs by Western ligand blots (WLB) before and during treatment. Combined treatment caused a higher increase in IGFBP-1 and larger suppression of total and free IGF-I, IGF-II, and IGFBP-3 (P <0.01 for all), but less suppression of IGFBP-2 (P <0.05) compared with tamoxifen monotherapy. An increase in IGFBP-2 ≥25% was associated with decreased progression-free survival (PFS) in the total patient population and combined treatment group. Similar response rates and time to progression in the treatment arms suggests moderate suppression of circulating IGF-I has no influence on clinical outcome.

Original language	English
Pages (from-to)	694-701
Number of pages	8
Journal	European Journal of Cancer
Volume	41
Issue number	5
DOIs	https://doi.org/10.1016/j.ejca.2004.12.015
Publication status	Published - Mar 2005

Keywords

Breast cancer
IGF-I
IGFBP-2
Octreotide
Tamoxifen

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/j.ejca.2004.12.015

Fingerprint Dive into the research topics of 'Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy'. Together they form a unique fingerprint.

Cite this

Helle, S. I., Mietlowski, W., Guastalla, J. P., Szakolczai, I., Bajetta, E., Sommer, H., Baltali, E., Pinter, T., Csepreghy, M., Ottestad, L., Boni, C., Bryce, C., Klijn, J. G. M., & Lønning, P. E. (2005). Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. European Journal of Cancer, 41(5), 694-701. https://doi.org/10.1016/j.ejca.2004.12.015

Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. / Helle, S. I.; Mietlowski, W.; Guastalla, J. P.; Szakolczai, I.; Bajetta, E.; Sommer, H.; Baltali, E.; Pinter, T.; Csepreghy, M.; Ottestad, L.; Boni, C.; Bryce, C.; Klijn, J. G M; Lønning, P. E.

In: European Journal of Cancer, Vol. 41, No. 5, 03.2005, p. 694-701.

Research output: Contribution to journal › Article › peer-review

Helle, SI, Mietlowski, W, Guastalla, JP, Szakolczai, I, Bajetta, E, Sommer, H, Baltali, E, Pinter, T, Csepreghy, M, Ottestad, L, Boni, C, Bryce, C, Klijn, JGM & Lønning, PE 2005, 'Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy', European Journal of Cancer, vol. 41, no. 5, pp. 694-701. https://doi.org/10.1016/j.ejca.2004.12.015

Helle, S. I. ; Mietlowski, W. ; Guastalla, J. P. ; Szakolczai, I. ; Bajetta, E. ; Sommer, H. ; Baltali, E. ; Pinter, T. ; Csepreghy, M. ; Ottestad, L. ; Boni, C. ; Bryce, C. ; Klijn, J. G M ; Lønning, P. E. / Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. In: European Journal of Cancer. 2005 ; Vol. 41, No. 5. pp. 694-701.

@article{5c614233dcef494895438a1a8f35e534,

title = "Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy",

abstract = "The insulin-like growth factor (IGF)-system was evaluated in 150 breast cancer patients participating in a randomised phase III trial comparing octreotide pamoate and tamoxifen with tamoxifen + placebo. Alterations in the IGF-system in the two treatment arms and individual changes with respect to outcome were compared. Serum IGF-I and -II, free IGF-I, and insulin-like growth factor binding protein 1-3 (IGFBP1-3) were measured by radioimmmunoassay (RIA)/immunoradiometric assay (IRMA) and IGFBPs by Western ligand blots (WLB) before and during treatment. Combined treatment caused a higher increase in IGFBP-1 and larger suppression of total and free IGF-I, IGF-II, and IGFBP-3 (P <0.01 for all), but less suppression of IGFBP-2 (P <0.05) compared with tamoxifen monotherapy. An increase in IGFBP-2 ≥25% was associated with decreased progression-free survival (PFS) in the total patient population and combined treatment group. Similar response rates and time to progression in the treatment arms suggests moderate suppression of circulating IGF-I has no influence on clinical outcome.",

keywords = "Breast cancer, IGF-I, IGFBP-2, Octreotide, Tamoxifen",

author = "Helle, {S. I.} and W. Mietlowski and Guastalla, {J. P.} and I. Szakolczai and E. Bajetta and H. Sommer and E. Baltali and T. Pinter and M. Csepreghy and L. Ottestad and C. Boni and C. Bryce and Klijn, {J. G M} and L{\o}nning, {P. E.}",

year = "2005",

month = mar,

doi = "10.1016/j.ejca.2004.12.015",

language = "English",

volume = "41",

pages = "694--701",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

number = "5",

}

TY - JOUR

T1 - Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy

AU - Helle, S. I.

AU - Mietlowski, W.

AU - Guastalla, J. P.

AU - Szakolczai, I.

AU - Bajetta, E.

AU - Sommer, H.

AU - Baltali, E.

AU - Pinter, T.

AU - Csepreghy, M.

AU - Ottestad, L.

AU - Boni, C.

AU - Bryce, C.

AU - Klijn, J. G M

AU - Lønning, P. E.

PY - 2005/3

Y1 - 2005/3

N2 - The insulin-like growth factor (IGF)-system was evaluated in 150 breast cancer patients participating in a randomised phase III trial comparing octreotide pamoate and tamoxifen with tamoxifen + placebo. Alterations in the IGF-system in the two treatment arms and individual changes with respect to outcome were compared. Serum IGF-I and -II, free IGF-I, and insulin-like growth factor binding protein 1-3 (IGFBP1-3) were measured by radioimmmunoassay (RIA)/immunoradiometric assay (IRMA) and IGFBPs by Western ligand blots (WLB) before and during treatment. Combined treatment caused a higher increase in IGFBP-1 and larger suppression of total and free IGF-I, IGF-II, and IGFBP-3 (P <0.01 for all), but less suppression of IGFBP-2 (P <0.05) compared with tamoxifen monotherapy. An increase in IGFBP-2 ≥25% was associated with decreased progression-free survival (PFS) in the total patient population and combined treatment group. Similar response rates and time to progression in the treatment arms suggests moderate suppression of circulating IGF-I has no influence on clinical outcome.

AB - The insulin-like growth factor (IGF)-system was evaluated in 150 breast cancer patients participating in a randomised phase III trial comparing octreotide pamoate and tamoxifen with tamoxifen + placebo. Alterations in the IGF-system in the two treatment arms and individual changes with respect to outcome were compared. Serum IGF-I and -II, free IGF-I, and insulin-like growth factor binding protein 1-3 (IGFBP1-3) were measured by radioimmmunoassay (RIA)/immunoradiometric assay (IRMA) and IGFBPs by Western ligand blots (WLB) before and during treatment. Combined treatment caused a higher increase in IGFBP-1 and larger suppression of total and free IGF-I, IGF-II, and IGFBP-3 (P <0.01 for all), but less suppression of IGFBP-2 (P <0.05) compared with tamoxifen monotherapy. An increase in IGFBP-2 ≥25% was associated with decreased progression-free survival (PFS) in the total patient population and combined treatment group. Similar response rates and time to progression in the treatment arms suggests moderate suppression of circulating IGF-I has no influence on clinical outcome.

KW - Breast cancer

KW - IGF-I

KW - IGFBP-2

KW - Octreotide

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=20044384178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044384178&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2004.12.015

DO - 10.1016/j.ejca.2004.12.015

M3 - Article

C2 - 15763644

AN - SCOPUS:20044384178

VL - 41

SP - 694

EP - 701

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 5

ER -